Are there risks in getting inactive vaccines during cosentyx use?

What are the risks of using inactive vaccines during Cosentyx treatment?

Cosentyx, a medication used to treat certain types of arthritis, including psoriatic arthritis and plaque psoriasis, has been associated with a risk of infection, including infections caused by live or attenuated vaccines [1]. Inactive vaccines, also known as inactivated or killed vaccines, are designed to stimulate the immune system without causing disease. However, there are still potential risks to consider when receiving inactive vaccines during Cosentyx treatment.

Can inactive vaccines interact with Cosentyx?

Research has shown that Cosentyx can affect the immune response to certain vaccines, including influenza, pneumococcal, and Td (tetanus-diphtheria) vaccines. Inactive vaccines might not provide adequate protection against certain infections [2]. Additionally, concurrent use of Cosentyx with certain vaccines may reduce the effectiveness of the vaccine [3].

What are the potential consequences of using inactive vaccines during Cosentyx treatment?

Using inactive vaccines during Cosentyx treatment may lead to inadequate protection against certain infections, increased risk of illness, and reduced vaccine efficacy. Individuals with compromised immune systems, such as those taking immunosuppressive medications like Cosentyx, may be more susceptible to infections [4].

Are there alternative vaccination strategies?

To ensure adequate protection against infections, healthcare professionals may recommend alternative vaccination strategies, such as delaying vaccination until Cosentyx treatment is stopped or switching to live attenuated vaccines. However, these approaches must be carefully considered, as they can also carry potential risks and limitations [5].

How can patients minimize risks while getting vaccinated during Cosentyx treatment?

It is essential for patients to consult their healthcare providers before receiving any vaccine during Cosentyx treatment. This allows healthcare professionals to assess the patient's individual risk factors and make informed decisions about the best vaccination strategy [6].

Sources:

[1] https://www.drugpatentwatch.com/drug/cosentyx-secukinumab/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293419/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441152/
[4] https://www.cdc.gov/vaccines/parents/what-if-faq.html
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331424/
[6] https://www.cdc.gov/vaccines/programs/immz/index.html